InvestorsHub Logo
Followers 62
Posts 7548
Boards Moderated 1
Alias Born 01/02/2003

Re: Denisk post# 412975

Tuesday, 07/25/2023 7:41:56 AM

Tuesday, July 25, 2023 7:41:56 AM

Post# of 425795
Denisk... "Mitigate was never intended as a clinical trial to reveal additional positive medical results for using Vascepa/ Vazkepa was only done to promote the distribution and sale of Vascepa to KP customers and patients.Total waste of time to talk about it." ...WRONG!!

IMO KP cares little to nothing about the distribution and sales of Vascepa to their customers...except as this might relate to KP's saving money by preserving the health of their customers.

Amarin, which provided the Vascepa to KP for for the study, as well as we investors, deserve to know the reason for it being stopped...and I am confident that the results will become known soon.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News